- Home
- TMCI vs AQST Comparison
TMCI vs AQST Comparison
Compare TMCI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMCI
- AQST
- Stock Information
- Founded
- TMCI 2014
- AQST 2004
- Country
- TMCI United States
- AQST United States
- Employees
- TMCI N/A
- AQST N/A
- Industry
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- TMCI Health Care
- AQST Health Care
- Exchange
- TMCI Nasdaq
- AQST Nasdaq
- Market Cap
- TMCI 449.2M
- AQST 390.4M
- IPO Year
- TMCI 2021
- AQST 2018
- Fundamental
- Price
- TMCI $7.07
- AQST $4.87
- Analyst Decision
- TMCI Hold
- AQST Strong Buy
- Analyst Count
- TMCI 5
- AQST 7
- Target Price
- TMCI $8.60
- AQST $10.29
- AVG Volume (30 Days)
- TMCI 320.3K
- AQST 2.4M
- Earning Date
- TMCI 11-04-2025
- AQST 11-03-2025
- Dividend Yield
- TMCI N/A
- AQST N/A
- EPS Growth
- TMCI N/A
- AQST N/A
- EPS
- TMCI N/A
- AQST N/A
- Revenue
- TMCI $213,751,000.00
- AQST $44,132,000.00
- Revenue This Year
- TMCI $10.63
- AQST N/A
- Revenue Next Year
- TMCI $9.43
- AQST $38.71
- P/E Ratio
- TMCI N/A
- AQST N/A
- Revenue Growth
- TMCI 7.67
- AQST N/A
- 52 Week Low
- TMCI $4.54
- AQST $2.12
- 52 Week High
- TMCI $10.79
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- TMCI 51.69
- AQST 59.98
- Support Level
- TMCI $6.93
- AQST $4.75
- Resistance Level
- TMCI $7.50
- AQST $5.27
- Average True Range (ATR)
- TMCI 0.32
- AQST 0.31
- MACD
- TMCI -0.07
- AQST 0.06
- Stochastic Oscillator
- TMCI 20.00
- AQST 60.96
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.